Certara

Guide

De-Risking Drug Design: How Early Feasibility Assessment Transforms Biotherapeutic Development

Learn how Early Feasibility Assessment and QSP modeling improve drug design, de-risk feasibility studies, &…

CertaraNovember 7, 2025

Publication

Towards new approach methodologies for biological therapeutics: a novel model-informed metric to assess immunogenicity risk

Immunogenicity poses a significant challenge in biotherapeutics development due to the formation of anti-drug antibodies…

Danielle PillsburyNovember 7, 2025

Fact Sheet

Build investor confidence with science-backed strategy

Discover expert insights on biotech funding, startup investment strategies, and securing capital for biotech ventures.…

CertaraNovember 6, 2025

Press Release

Certara Reports Third Quarter 2025 Financial Results

RADNOR, PA— November 6, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development,…

CertaraNovember 6, 2025

Webinar

Failure to Launch: Building Smarter Strategies to Get the Right Drug to the Right Patient

CertaraNovember 6, 2025

White Paper

Web of Evidence: A Practical Guide to Managing Document Dependencies in eCTD Submissions

Discover a practical framework to plan, author, and manage regulatory submissions using document dependency mapping.

CertaraNovember 6, 2025

Publication

Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

This study demonstrates how model-informed approaches can improve dose selection decisions when direct clinical comparisons…

CertaraNovember 5, 2025

Press Release

Certara Automates Scientific Workflows with Phoenix® Cloud

Certara has released TFL studio, a module in its cloud-native PK/PD software, Phoenix Cloud, to…

CertaraNovember 4, 2025

Webinar

Delivering on Deadline: Navigating Regulatory Submissions with Pharmacometrics Insights

Danielle PillsburyNovember 3, 2025

Blog

Empowering the PK Community: Insights from the Phoenix® User Events

Explore insights from the Phoenix User Events in Europe, where experts shared innovations in automation,…

CertaraNovember 3, 2025

De-Risking Drug Design: How Early Feasibility Assessment Transforms Biotherapeutic Development

Towards new approach methodologies for biological therapeutics: a novel model-informed metric to assess immunogenicity risk

Build investor confidence with science-backed strategy

Certara Reports Third Quarter 2025 Financial Results

Failure to Launch: Building Smarter Strategies to Get the Right Drug to the Right Patient

Web of Evidence: A Practical Guide to Managing Document Dependencies in eCTD Submissions

Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

Certara Automates Scientific Workflows with Phoenix® Cloud

Delivering on Deadline: Navigating Regulatory Submissions with Pharmacometrics Insights

Empowering the PK Community: Insights from the Phoenix® User Events

Newsletter sign up

Quick links

Solutions

Contact